与可逆大脑血管收缩综合征相关的药物:在vigiBase®中进行的一项药监测研究
Sylvie Favrelière1, Julien Mahé2, Gwenaelle Veyrac2
1Service de Pharmacologie Clinique - Centre Régional de Pharmacovigilance de Poitiers, CHU Poitiers, Poitiers, France.
Cephalalgia : an international journal of headache
|August 10, 2024
概括
药物诱导的可逆大脑血管收缩综合征 (RCVS) 是罕见的. 这项研究确定了抗抑郁药和类药物是常见的原因,并标记了14种新的RCVS潜在药物触发剂.
科学领域:
- 药物监督 药物监督 药物监督
- 神经学 神经学
- 临床药理学 临床药理学
背景情况:
- 药物诱导的可逆大脑血管收缩综合征 (RCVS) 数据有限.
- 了解药物相关性对于患者安全至关重要.
研究的目的:
- 描述与已知的致病药物相关的RCVS.
- 为了确定新的潜在的药物触发RCVS.
主要方法:
- 使用VigiBase®用于RCVS报告,截至2023年5月.
- 对已知药物类进行了描述性研究.
- 进行不成比例分析以检测新的药物信号.
主要成果:
- 分析了560份RCVS报告,主要是18-64岁的女性.
- 抗抑郁剂 (38.4%),免疫抑制剂 (8.7%),三 (6.4%) 和鼻腔止血剂 (3.7%) 是关键的药物类别.
- 确定了14种具有不成比例信号的药物,包括葡萄糖皮质类药物,布洛普和单克隆抗体.
结论:
- 证实了RCVS中的血管缩作用,特别是在组合疗法中.
- 突出了RCVS的潜在阳性原因,有助于临床诊断.
- 表明新的药物信号需要进一步调查RCVS风险.
相关概念视频
Pharmacovigilance
801
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
801
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
276
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
276
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
804
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
804
Antiepileptic Drugs: Potassium Channel Activators
152
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
152
Drug Delivery: Parenteral Route
453
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
453
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K


